RDUS - Radius Health, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
17.51
+0.56 (+3.30%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close16.95
Open17.06
Bid16.12 x 1300
Ask19.95 x 800
Day's Range16.64 - 17.56
52 Week Range12.81 - 41.16
Volume317,344
Avg. Volume800,001
Market Cap797.397M
Beta (3Y Monthly)1.61
PE Ratio (TTM)N/A
EPS (TTM)-5.57
Earnings DateMay 4, 2017 - May 8, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est35.86
Trade prices are not sourced from all markets
  • Markit2 days ago

    See what the IHS Markit Score report has to say about Radius Health Inc.

    # Radius Health Inc ### NASDAQ NMS:RDUS View full report here! ## Summary * Bearish sentiment is moderate ## Bearish sentiment Short interest | Positive Short interest is moderate for RDUS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $2.34 billion over the last one-month into ETFs that hold RDUS are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Radius Exceeds 2018 Financial Guidance, Provides Updates
    Zacks10 days ago

    Radius Exceeds 2018 Financial Guidance, Provides Updates

    Radius (RDUS) exceeds its 2018 financial guidance, with full-year U.S. net sales of its lead drug Tymlos surpassing the upper range of $95-$98 million.

  • GlobeNewswire12 days ago

    Radius Exceeds 2018 Financial Guidance and Provides Business Update at the 37th Annual J.P. Morgan Healthcare Conference

    Radius Health, Inc. (RDUS), today announced that it has exceeded its 2018 financial guidance with full-year TYMLOS® U.S. net sales surpassing the upper range of $95 to $98 million. 2019 will be a pivotal year for us as we move closer to our goal of U.S. anabolic market leadership and expect to advance our late-stage clinical pipeline of two innovative Phase 3 products, elacestrant and abaloparatide-patch, both with blockbuster potential,” said Jesper Hoeiland, President and Chief Executive Officer of Radius. Elacestrant’s Phase 3 EMERALD study was initiated in December 2018.

  • GlobeNewswire16 days ago

    Radius Health to Present at the 37th Annual J.P. Morgan Healthcare Conference

    WALTHAM, Mass., Jan. 02, 2019 -- Radius Health, Inc. (Nasdaq: RDUS), today announced that President and Chief Executive Officer, Jesper Høiland, will present a corporate update.

  • Markitlast month

    See what the IHS Markit Score report has to say about Radius Health Inc.

    # Radius Health Inc ### NASDAQ NMS:RDUS View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is moderate for RDUS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding RDUS are favorable, with net inflows of $1.91 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Hedge Funds Are Buying Radius Health Inc (RDUS)
    Insider Monkeylast month

    Hedge Funds Are Buying Radius Health Inc (RDUS)

    Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The one and a half month time period since the end of the […]

  • GlobeNewswire2 months ago

    Radius Health Provides Updates on its Oncology Programs and Announces Scientific Presentations at 2018 San Antonio Breast Cancer Symposium (SABCS)

    Phase 3 elacestrant study has opened for enrollmentFast Track designation from the FDA for the Phase 3 study populationElacestrant pre-clinical data demonstrates further.

  • Radius Health (RDUS) Sees Hammer Chart Pattern: Time to Buy?
    Zacks2 months ago

    Radius Health (RDUS) Sees Hammer Chart Pattern: Time to Buy?

    Radius Health, Inc. (RDUS) has been struggling lately, but the selling pressure may be coming to an end soon.

  • See what the IHS Markit Score report has to say about Radius Health Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Radius Health Inc.

    Radius Health Inc NASDAQ NMS:RDUS

  • GlobeNewswire2 months ago

    Recent Analysis Shows InterDigital, Alpha and Omega Semiconductor, Alliance Resource Partners, Aircastle, XPO Logistics, and Radius Health Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Nov. 07, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of RDUS earnings conference call or presentation 1-Nov-18 12:00pm GMT

    Q3 2018 Radius Health Inc Earnings Call

  • Radius Health (RDUS) Posts Narrower-Than-Expected Q3 Loss
    Zacks3 months ago

    Radius Health (RDUS) Posts Narrower-Than-Expected Q3 Loss

    Radius Health (RDUS) posts narrower Q3 loss as Tymlos sales gains traction.

  • See what the IHS Markit Score report has to say about Radius Health Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Radius Health Inc.

    Short interest is moderate for RDUS with between 5 and 10% of shares outstanding currently on loan. The net inflows of $1.98 billion over the last one-month into ETFs that hold RDUS are not among the highest of the last year and have been slowing.

  • Why Radius Health Is Soaring Today
    Motley Fool3 months ago

    Why Radius Health Is Soaring Today

    Shares push hire after the company reports earnings. Here's what investors need to know.

  • Associated Press3 months ago

    Radius Health: 3Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had a loss of $1.09 per share. Losses, adjusted for stock option expense and non-recurring costs, came to 85 cents per share. The biotechnology company ...

  • GlobeNewswire3 months ago

    Radius Health Announces Third Quarter 2018 Operating Results and Financial Guidance for FY 2018 and FY 2019

    TYMLOS® U.S. net sales continued to increase in the third quarter of 2018, totaling $27.6 million.2019 Medicare Part D coverage for TYMLOS increased from 44% to 64%.

  • See what the IHS Markit Score report has to say about Radius Health Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Radius Health Inc.

    Short interest is moderate for RDUS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • See what the IHS Markit Score report has to say about Radius Health Inc.
    Markit4 months ago

    See what the IHS Markit Score report has to say about Radius Health Inc.

    Radius Health Inc NASDAQ NMS:RDUS

  • See what the IHS Markit Score report has to say about Radius Health Inc.
    Markit4 months ago

    See what the IHS Markit Score report has to say about Radius Health Inc.

    Radius Health Inc NASDAQ NMS:RDUS